Boehringer Ingelheim has entered into a research collaboration agreement with and Circuit Therapeutics to discover new ways of treating psychiatric disorders.
As per the deal, the companies will combine their research and development capabilities to offer a pathway for the drug discovery in a three-year research program.
Circuit Therapeutics will offer an innovative platform to help in identification and characterisation of drug targets from brain circuits involved in normal and pathological behaviors.
The company will also use its optogenetics technology, which allows the control of individual nerve cells and circuits within the brain, in combination with the molecular technologies to support the drug development.
Circuit Therapeutics chairman Fred Moll the vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with the company's technologies makes an ideal partnership.
"We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients' lives," Moll added.
Boehringer Ingelheim neuroscience research head Bernd Sommer said, "We believe that, by working together to investigate maladaptive brain circuitry with this exciting approach, we will be able to obtain a better understanding of the neurobiological basis of human neuropsychiatric disorders, thereby allowing us to make a difference to science, disease and patients."
